Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
ANZ J Surg. 2020 Apr;90(4):602-607. doi: 10.1111/ans.15486. Epub 2019 Nov 19.
The left atrial maze IV (LAM-IV) alone has been used to eliminate atrial fibrillation (AF) without severe right heart diseases. However, we felt that it could be improved and developed a modified LAM-IV (MLAM-IV). In this prospective trial, we aimed to investigate 5-year clinical outcomes of AF in patients treated by the novel MLAM-IV technique.
Between September 2012 and October 2013, 120 patients who underwent valve surgery and bipolar radiofrequency ablation for AF were randomized into the LAM-IV group (n = 60) or MLAM-IV group (n = 60). At postoperative follow-up examinations, data were recorded at 1, 3 and 6 months, and annually thereafter.
The mean ablation time and postoperative ventilation time were shorter in the MLAM-IV group than in the LAM-IV group (P < 0.001 and P = 0.03, respectively). At 5 years, the rate of freedom from AF was 69.0% in the MLAM-IV group and 60.0% in the LAM-IV group (hazard ratio 0.71, 95% confidence interval 0.39 to 1.32, P = 0.42). There were no differences with respect to the early operative mortality and major complications, late mortality, and major adverse events.
The MLAM-IV provides a technically simpler ablation process. The MLAM-IV was associated with less ventilation support in the early postoperative period. The long-term efficacy of the MLAM-IV in the treatment of AF is comparable to that of the LAM-IV.
单纯左心房迷宫术 IV 型(LAM-IV)已被用于消除无严重右心疾病的心房颤动(AF)。然而,我们认为它可以改进和发展一种改良的 LAM-IV(MLAM-IV)。在这项前瞻性试验中,我们旨在研究采用新型 MLAM-IV 技术治疗的 AF 患者的 5 年临床结局。
2012 年 9 月至 2013 年 10 月,120 例行瓣膜手术和双极射频消融治疗 AF 的患者被随机分为 LAM-IV 组(n = 60)或 MLAM-IV 组(n = 60)。在术后随访检查中,记录 1、3 和 6 个月以及此后每年的数据。
MLAM-IV 组的平均消融时间和术后通气时间短于 LAM-IV 组(P < 0.001 和 P = 0.03)。5 年时,MLAM-IV 组无 AF 发生率为 69.0%,LAM-IV 组为 60.0%(风险比 0.71,95%置信区间 0.39 至 1.32,P = 0.42)。两组在早期手术死亡率和主要并发症、晚期死亡率和主要不良事件方面无差异。
MLAM-IV 提供了一种技术上更简单的消融过程。MLAM-IV 在术后早期通气支持较少。MLAM-IV 治疗 AF 的长期疗效与 LAM-IV 相当。